1. Home
  2. QLGN vs SNAX Comparison

QLGN vs SNAX Comparison

Compare QLGN & SNAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • SNAX
  • Stock Information
  • Founded
  • QLGN 1996
  • SNAX 2017
  • Country
  • QLGN United States
  • SNAX United States
  • Employees
  • QLGN N/A
  • SNAX N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • SNAX Packaged Foods
  • Sector
  • QLGN Health Care
  • SNAX Consumer Staples
  • Exchange
  • QLGN Nasdaq
  • SNAX Nasdaq
  • Market Cap
  • QLGN 3.4M
  • SNAX 3.1M
  • IPO Year
  • QLGN N/A
  • SNAX N/A
  • Fundamental
  • Price
  • QLGN $4.18
  • SNAX $0.63
  • Analyst Decision
  • QLGN
  • SNAX
  • Analyst Count
  • QLGN 0
  • SNAX 0
  • Target Price
  • QLGN N/A
  • SNAX N/A
  • AVG Volume (30 Days)
  • QLGN 54.9K
  • SNAX 54.9K
  • Earning Date
  • QLGN 11-14-2024
  • SNAX 11-13-2024
  • Dividend Yield
  • QLGN N/A
  • SNAX N/A
  • EPS Growth
  • QLGN N/A
  • SNAX N/A
  • EPS
  • QLGN N/A
  • SNAX N/A
  • Revenue
  • QLGN N/A
  • SNAX $19,364,939.00
  • Revenue This Year
  • QLGN N/A
  • SNAX $30.31
  • Revenue Next Year
  • QLGN N/A
  • SNAX N/A
  • P/E Ratio
  • QLGN N/A
  • SNAX N/A
  • Revenue Growth
  • QLGN N/A
  • SNAX N/A
  • 52 Week Low
  • QLGN $3.34
  • SNAX $0.55
  • 52 Week High
  • QLGN $30.50
  • SNAX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 43.01
  • SNAX 26.04
  • Support Level
  • QLGN $3.53
  • SNAX $0.55
  • Resistance Level
  • QLGN $4.39
  • SNAX $0.94
  • Average True Range (ATR)
  • QLGN 0.33
  • SNAX 0.07
  • MACD
  • QLGN 0.06
  • SNAX -0.02
  • Stochastic Oscillator
  • QLGN 50.98
  • SNAX 22.88

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About SNAX Stryve Foods Inc.

Stryve Foods Inc is a healthy snacking company that manufactures, markets, and sells differentiated healthy snacking products. The company offers convenient snacks that are lower in sugar and carbohydrates and higher in protein than other snacks.

Share on Social Networks: